Utilizing a cell line with high GPC3 expression in an immunocompromised xenograft does not adequately represent the complex human HCC tumor microenvironment and favors the function of our GPC3-targeting agents; however, this proof-of-concept study was important to demonstrate the potential of our platform. This evidence concerns the gene GPC3 and hepatocellular carcinoma.